Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

R Romualdo Barroso-Sousa (Brasilia Hospital, Rede Américas, Brasilia, Brazil) J Jorge Gómez Tejeda Zañudo T Tianyu Li S Sangeetha M. Reddy L Leisha A. Emens T Thomas M. Kuntz C Carolina Alves Costa Silva S Saud H. AlDubayan H Hoyin Chu B Beth Overmoyer P Paulina Lange M Molly K. DiLullo M Meagan Montesion J Julie Kasparian M Melissa E. Hughes V Victoria Attaya A Ameer Basta N Nancy U. Lin N Nabihah Tayob R Rinath Jeselsohn E Elizabeth A. Mittendorf S Sara M. Tolaney (Department of Medical Oncology, Dana-Farber Cancer Institute)

Article Details

Volume / Issue Vol. 16, Issue 1
Published May 13, 2025
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (22)

R

Romualdo Barroso-Sousa

Brasilia Hospital, Rede Américas, Brasilia, Brazil

J

Jorge Gómez Tejeda Zañudo

T

Tianyu Li

S

Sangeetha M. Reddy

L

Leisha A. Emens

T

Thomas M. Kuntz

C

Carolina Alves Costa Silva

S

Saud H. AlDubayan

H

Hoyin Chu

B

Beth Overmoyer

P

Paulina Lange

M

Molly K. DiLullo

M

Meagan Montesion

J

Julie Kasparian

M

Melissa E. Hughes

V

Victoria Attaya

A

Ameer Basta

N

Nancy U. Lin

N

Nabihah Tayob

R

Rinath Jeselsohn

E

Elizabeth A. Mittendorf

S

Sara M. Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute